PTC Therapeutics (PTCT) announced the FDA has accepted for filing the New Drug Application of sepiapterin for the treatment of pediatric and adult patients living with phenylketonuria. A PDUFA target action date is expected to be provided in the Day 74 Letter. The sepiapterin NDA is based on the results from the phase 3 APHENITY trial.
Matthew Klein, CEO of PTC Therapeutics, said: "The clinical trial data, including the evidence of enabling diet liberalization, support that sepiapterin can provide significant benefit to PKU patients, helping to meet the persistent, significant unmet need in this community."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.